Mosanna Therapeutics Launches with $80 Million to Advance Novel Nighttime Nasal Spray for Obstructive Sleep Apnea 

• Series A Funding to Advance MOS118 through Phase 2 Clinical Trials 
• Biotech Veteran David Weber Appointed CEO to Drive Clinical Development 
• Obstructive sleep apnea affects nearly 1 billion people globally, with the majority undiagnosed and underserved with current treatment options 

Mosanna Therapeutics, a biotech company rethinking treatment of obstructive sleep apnea (OSA), today announced the close of $80 million in Series A funding. The company is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea that will help restore the body’s natural airway control. The financing was led by Pivotal bioVenture Partners and EQT Life Sciences, along with Forbion, Broadview Ventures, and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures as well as Supermoon Capital and High-Tech Gründerfonds (HTGF). 

OSA is the most common sleep-related breathing disorder, affecting an estimated 1 billion people globally. Left untreated, OSA is linked to serious health risks including hypertension, cardiovascular disease, stroke, depression and excessive daytime sleepiness – contributing to workplace and car accidents. Despite OSA’s prevalence, treatment has largely focused on mechanical solutions that are often uncomfortable and disruptive. 

Mosanna is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at bedtime that helps restore the body’s natural airway reflex. MOS118 targets the upper airway muscles that are responsible for maintaining airway patency. Research has shown that, for reasons yet unknown, the natural airway reflex in OSA patients exhibits decreased activity during sleep resulting in loss of airway patency and apnea. The new funding will support the advancement of MOS118 through Phase 2 development while also supporting expansion of Mosanna’s pipeline. 

Mosanna also appointed veteran biotech leader David Weber, Ph.D., as President and Chief Executive Officer to guide Mosanna’s next stage of growth. With more than 30 years of experience spanning drug development, capital formation and corporate strategy, Dr. Weber has led teams across both public and private life sciences companies. Dr. Weber was also appointed to Mosanna’s Board of Directors. 

“What sets Mosanna apart is its fundamentally different approach to sleep apnea, treating it as a neurological and muscular dysfunction rather than a purely mechanical issue,” said Daniela Begolo, Ph.D., Managing Director with EQT Life Sciences. “MOS118 is the first therapy with the potential to restore the body’s natural airway reflex with the simplicity of a nasal spray. MOS118 has the potential to dramatically improve adherence and outcomes in a patient population that has long been underserved.” 

“With his deep expertise in biotech innovation and patient-centric therapies, Dr. Weber was the ideal choice to lead Mosanna into the next chapter,” said Jeni Lee, Ph.D., Partner with Pivotal bioVentures Partners. “We look forward to partnering with him and the Mosanna team to deliver on the promise of this life-changing sleep apnea treatment.” 

“Mosanna is taking a truly transformational approach to sleep apnea treatment – offering a non-invasive, non-mechanical solution designed to seamlessly fit into daily life,” said Dr. Weber. “No one has sleep apnea while awake, because our bodies instinctively keep the airway open. Mosanna simply helps to restore this natural reflex during sleep – delivering a nasal spray alternative to invasive mechanical workarounds. With this funding, we’re accelerating development to bring this groundbreaking treatment to patients who desperately need better options.” 

With this funding, Drs. Begolo and Lee joined the Board of Directors alongside Dmitrij Hristodorov, Ph.D., General Partner at Forbion; Hewmun Lau, M.B.A., Principal at Broadview Ventures; and Tiba Aynechi, Ph.D., General Partner at Norwest. They join existing board directors Sascha Oliver Bucher, M.B.A., CEFA, co-founder and Partner at Forty51 Ventures; and veteran biotech CEO Ben Machielse, who also serves as board chair.  

---

About Mosanna Therapeutics  
Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body’s natural airway control during sleep, Mosanna’s lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial. Founded in 2022, the company has raised more than $80 million from investors including Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds (HTGF). Mosanna has offices in Redwood City, California and Basel, Switzerland. For more information, visit mosanna.com. 

Media Contact 
Jessica Flick 
Cogenta Communications 
jessica@cogentacom.com  

About HTGF – High-Tech Gründerfonds 
HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved almost 200 successful exits.  
Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices.  
For more information, please visit HTGF.de or follow us on LinkedIn.   

Media contact 
High-Tech Gründerfonds Management GmbH 
Tobias Jacob, Senior Marketing & Communications Manager  
T.: +49 228 – 82300 – 121
t.jacob@htgf.de